Autoimmune Hemolytic Anemia Diagnosis and Management

Autoimmune haemolytic anaemia (AIHA) comprises a group of disorders in which autoantibodies target erythrocytes, leading to premature red-cell destruction. The condition is broadly classified into warm antibody AIHA, in which IgG antibodies react at body temperature, and cold agglutinin disease, driven by complement-fixing IgM at low temperatures. Diagnosis hinges on clinical features of anaemia and haemolysis, supported by laboratory parameters such as elevated lactate dehydrogenase, unconjugated bilirubin and reticulocytosis, together with reduced haptoglobin. The direct antiglobulin test (DAT) remains the cornerstone for immunohaematological confirmation, although DAT-negative cases require further serological or flow-cytometric evaluation.

First-line management of warm AIHA typically involves high-dose corticosteroids, with most patients achieving an initial response. Second-line options include the anti-CD20 monoclonal antibody rituximab and, where indicated, splenectomy. In cold agglutinin disease, splenectomy and steroids play a limited role; rituximab alone or in combination with cytotoxic agents has become standard. Supportive measures—transfusion when necessary, thromboprophylaxis and correction of nutritional deficiencies—are integral. Recent insights into disease mechanisms have spurred development of targeted agents: inhibitors of the neonatal Fc receptor, spleen tyrosine kinases and complement components C1s or C3, promising improved tolerability and efficacy in refractory cases.

Personalised treatment algorithms now seek to align drug mechanism with autoantibody class and complement involvement, while minimising long-term immunosuppression. Multidisciplinary care, close monitoring of haemolytic markers and proactive management of complications such as thrombosis and infections underpin optimal outcomes in this heterogeneous disorder.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Autoimmune Hemolytic Anemia Diagnosis and Management publication trend

The graph below shows the total number of articles in autoimmune hemolytic anemia diagnosis and management across all publications each year (not limited to Nature Index journals).

Technical terms

Autoimmune haemolytic anaemia (AIHA): A disorder characterised by premature red-cell destruction mediated by autoantibodies.

Direct antiglobulin test (DAT): Laboratory assay detecting antibodies or complement bound to erythrocytes, confirming immune-mediated haemolysis.

Warm antibody AIHA: Variant of AIHA in which IgG autoantibodies react optimally at 37 °C, leading to extravascular haemolysis.

Cold agglutinin disease (CAD): Form of AIHA mediated by complement-fixing IgM autoantibodies active at low temperatures, causing intravascular and extravascular haemolysis.

Complement cascade: Series of proteolytic reactions in plasma that amplify immune responses and mediate cell lysis.

Spleen tyrosine kinase (SYK) inhibitor: Small-molecule drug that blocks intracellular signalling crucial for antibody-mediated phagocytosis of erythrocytes.

References

1. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double‐blind, placebo‐controlled, global study (FORWARD). American Journal of Hematology (2023).
2. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Disease Markers (2015).
3. The Changing Landscape of Autoimmune Hemolytic Anemia. Frontiers in Immunology (2020).
4. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Frontiers in Immunology (2020).
5. Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of Complement and Potential New Targets for Therapy. BioMed Research International (2015).
6. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLOS ONE (2018).